| 1 |
33389441 | The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico. | 2022 Feb |
3 |
| 2 |
35185356 | Insight into the biological impact of COVID-19 and its vaccines on human health. | 2022 May |
2 |
| 3 |
35510477 | Dual targeting of RdRps of SARS-CoV-2 and the mucormycosis-causing fungus: an in silico perspective. | 2022 Jul |
2 |
| 4 |
32338164 | SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective. | 2021 Jun |
1 |
| 5 |
33693066 | Structural analogues of existing anti-viral drugs inhibit SARS-CoV-2 RNA dependent RNA polymerase: A computational hierarchical investigation. | 2021 Mar |
1 |
| 6 |
34216889 | In silico analysis of RNA-dependent RNA polymerase of the SARS-CoV-2 and therapeutic potential of existing antiviral drugs. | 2021 Aug |
4 |
| 7 |
32222463 | Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. | 2020 Jul 15 |
2 |
| 8 |
32387040 | Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial? | 2020 Aug |
1 |
| 9 |
32419838 | Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment. | 2020 |
1 |
| 10 |
32511320 | Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase. | 2020 Mar 20 |
1 |
| 11 |
32562705 | A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19. | 2020 Aug |
1 |
| 12 |
32692185 | Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19. | 2020 Nov 6 |
1 |
| 13 |
33287144 | Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge. | 2020 Dec 3 |
1 |